IBRX Sales Soar 2,540%
Revenue (GAAP) soared to $26.4 million in Q2 2025, beating GAAP revenue estimates by 14.0%.
Net loss per share (GAAP) improved to ($0.10), ahead of expectations.
ANKTIVA sales and international launches fueled top-line growth, but heavy net losses and cash burn remain.
These 10 stocks could mint the next wave of millionaires ›
ImmunityBio (NASDAQ:IBRX), a commercial-stage biotechnology company, released its second-quarter results on August 5, 2025. The main headline: revenue (GAAP) jumped to $26.4 million, soundly beating analyst GAAP revenue estimates of $23.15 million, as commercial sales of the immunotherapy ANKTIVA accelerated. Net loss per share (GAAP) narrowed to ($0.10), better than the projected ($0.11 GAAP EPS) and improving sharply from ($0.20) GAAP per share a year earlier. Overall, the quarter showed surging product revenue and reduced losses, even as the company maintained significant levels of R&D spending and faced regulatory hurdles.
Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change
EPS (GAAP) $(0.10) $(0.11) $(0.20) 50.0%
Revenue $26.4 million $23.15 million $1.0 million 2,540.0%
Research & Development Expense $52.4 million N/A N/A
Selling, General & Administrative Expense N/A $48.6 million N/A
Net Loss Attributable to Common Stockholders $(92.6 million) $(134.6 million) -31.2%
Cash, Cash Equivalents & Marketable Securities $153.7 million $149.8 million* 2.6%
Source: Analyst estimates for the quarter provided by FactSet.
ImmunityBio's Business and Recent Focus
ImmunityBio is an immunotherapy company developing treatments that stimulate a patient's own immune system to fight cancer and other diseases. Its pipeline combines biologic drugs, vaccine vectors, and cell therapies. The lead product is ANKTIVA, an antibody-cytokine fusion protein designed to amplify the immune system's attack against tumors.
Recently, the company has focused on ramping up commercial sales of ANKTIVA for bladder cancer and expanding into global markets. At the same time, it continues to invest in a diverse pipeline, partnering with industry peers and scaling up its in-house manufacturing facilities. Key success factors include gaining further regulatory approvals, maintaining robust ANKTIVA sales growth, and advancing other product candidates into late-stage trials.
Quarter in Review: Financial and Operational Performance
Revenue (GAAP) saw a massive jump of 60% compared to Q1 2025, mainly due to rising sales of ANKTIVA for bladder cancer. The product brought in robust demand across U.S. urology practices of all sizes. GAAP revenue soared from just $1.0 million in Q2 2024. ANKTIVA unit sales surged 246% in the first half of 2025 over the second half of 2024, after the assignment of a J-code, which allows for easier reimbursement by insurers.
International momentum was also notable, with the UK Medicines and Healthcare products Regulatory Agency (MHRA) approving marketing for ANKTIVA in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). However, regulatory speed bumps persisted. In the U.S, the Food and Drug Administration (FDA) issued a "Refuse to File" letter on the supplemental application for ANKTIVA in papillary-only NMIBC. ImmunityBio will need to conduct a new randomized controlled trial, which will involve added time and cost. The company also applied to the National Comprehensive Cancer Network (NCCN) for a guideline expansion to include papillary-only disease in BCG-unresponsive NMIBC, with a decision due in August 2025.
On the pipeline front, ImmunityBio pushed forward with new product development. It launched a pivotal randomized trial called ResQ201A for non-small cell lung cancer (NSCLC). This combines N-803, its proprietary cytokine fusion protein, with tislelizumab, a PD-1 checkpoint inhibitor medicine from BeOne Medicines, aiming for use as second-line therapy. The company also reached full trial enrollment in a National Cancer Institute study of ANKTIVA plus adenovirus vaccine for patients with Lynch syndrome, a hereditary cancer risk syndrome. Expansion of clinical trials into Europe and Asia is in process, and the FDA indicated support for the company's lymphopenia program, which focuses on restoring immune cell counts in cancer patients.
Strategic collaborations continued playing a role. ImmunityBio deepened its work with BeOne Medicines and kept leveraging the Serum Institute of India's expertise for manufacturing a recombinant BCG treatment, used to address shortages for bladder cancer therapies in the U.S. More than 150 patients received this treatment under expanded access protocols. Manufacturing expansions to support growing ANKTIVA production remained a focus, reflecting higher manufacturing and distribution outlays as well as license fees.
Looking Ahead: Guidance and Watch List
Management did not provide explicit forward guidance for the next quarter or for fiscal 2025. In comments, the leadership highlighted priorities around expanding ANKTIVA's reach in the U.S. and UK, progressing regulatory filings, and advancing several new pipeline trials. Management also pointed to a recent $80 million equity raise in July 2025, plus potential new warrant proceeds that could extend its cash runway.
These include additional regulatory decisions, ongoing cash burn and fundraising needs, the continued pace of domestic ANKTIVA sales, and the company's ability to deliver on large late-stage trial commitments for new indications. Heavy net losses and a substantial cash burn mean financial discipline will be key as ImmunityBio navigates commercialization and pipeline growth. ImmunityBio does not currently pay a dividend.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,039%* — a market-crushing outperformance compared to 181% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
*Stock Advisor returns as of August 4, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
4 minutes ago
- National Post
Mark Carney's popularity cooling off in the summer, but still remains broadly positive: poll
A new poll suggests Prime Minister Mark Carney's popularity is cooling off in the summer, but still remains broadly positive. Article content Abacus Data says the Carney-led Liberal government's approval dipped to 50 per cent in its latest polling, down two percentage points compared to mid-July and the lowest level since March. Article content Canadians were surveyed in the week after U.S. President Donald Trump levied new 35 per cent tariffs on Canada — seemingly a consequence of failing to secure a new trade deal by the Aug. 1 deadline. Article content Article content Article content Carney himself maintains a positive net approval rating despite a couple percentage points of mild cooling. Article content Article content
Globe and Mail
5 hours ago
- Globe and Mail
3 Reasons to Buy Carnival Stock Like There's No Tomorrow
Key Points Carnival's revenue continues to reach record levels, with the business benefiting from strong demand for cruise travel. Rising profits have helped the management team reduce the company's debt burden. Even though the stock has rocketed higher, investors will be drawn to the current valuation. 10 stocks we like better than Carnival Corp. › Carnival (NYSE: CCL) continues sailing in the right direction, something its shareholders have become extremely optimistic about. That's not a surprise, given that the cruise line business was decimated by the COVID-19 pandemic. However, the company is on much better footing these days as it serves robust demand from consumers. In the past 12 months, shares have soared 104% (as of Aug. 6), showcasing heightened bullishness. Despite this monster performance, here are three reasons why investors should still consider buying this travel stock like there's no tomorrow. Durable demand Carnival's business has benefited from tremendous momentum. During the fiscal 2025 second quarter (ended May 31), the company reported record revenue of $6.3 billion. This figure was up 9.5% year over year and 164% higher than the same period of fiscal 2022. There's clearly strong demand from travelers. Carnival had a whopping $8.5 billion in customer deposits in Q2, a record. Net yields, a measure of a cruise line's pricing power, came in at a record $200.07, after increasing by 7.2% during the second quarter. This was "driven by close-in strength in ticket prices and continued strong onboard spending," CFO David Bernstein said on the Q2 2025 earnings call. The demand for Carnival has been impressive in the years following the pandemic's disruption. Investors might think that the good times will come to an end soon. While the rapid growth the business has registered won't continue indefinitely, there's still reason to remain optimistic over the long term. The cruise industry faces some favorable tailwinds. For instance, younger travelers are more interested in these vacations. There are also more first-time passengers coming aboard. As it pushes to capture the opportunity ahead, Carnival is investing in building new cruise ships. It just opened a new private destination, called the Celebration Key, in July. What's more, Carnival is upgrading its rewards program, which will launch in 2026. This can boost customer loyalty and drive repeat cruise trips. Financial improvements During the pandemic, Carnival was forced to pause its operations. To survive the revenue hit, management had to take on more debt to fund the business. It's understandable if, at the time, investors were worried that Carnival would never get out of its predicament. With each passing quarter these days, the company is making substantial progress when it comes to its financial situation. During Q2, Carnival's operating income increased 66.8% year over year to $934 million. This was another record. To its credit, the business is starting to benefit from being able to better leverage its costs as revenue rises. Cruise and tour operating expenses were up just 2.3% year over year during the second quarter. With profitability showing major improvements, Carnival has been able to clean up its balance sheet as well. It ended Q2 with $27.3 billion of long-term debt, a balance that has been reduced by 20% in the past three years. The company's credit rating was also upgraded by two major agencies, which is a vote of confidence. Carnival's upside Carnival's stock has been a huge winner. However, the valuation is still compelling for new investors, even though the company is operating at a very high level these days. The price-to-earnings (P/E) ratio of 15.8 is no doubt cheap, representing a 36% discount to the overall S&P 500 index. Should the P/E multiple get closer to the benchmark's level, there is sizable upside for patient investors. Carnival's strong demand, improving financials, and attractive valuation are three reasons to buy the stock like there's no tomorrow. Should you invest $1,000 in Carnival Corp. right now? Before you buy stock in Carnival Corp., consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Carnival Corp. wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
5 hours ago
- Globe and Mail
The Great Flattening is a quiet evolution as middle managers decline
This is the weekly Work Life newsletter. If you are interested in more careers-related content, sign up to receive it in your inbox. Have you noticed fewer rungs on the corporate ladder lately? For the last few years, as companies invest more capital into artificial intelligence, Big Tech has been cutting layers of management in what's become known as the 'Great Flattening.' Now, new data from Gusto, which provides payroll and HR solutions, shows small and mid-sized businesses (SMBs) are following suit and it's reshaping the way teams are structured, developed and led. From 2022 to 2024, the number of individual contributors per people manager at SMBs has doubled. Back in 2019, managers typically oversaw about three direct reports. Now, that number is about six. Nich Tremper, senior economist at Gusto, says this isn't simply a result of sweeping layoffs, but rather a quiet evolution. 'What seems to be happening is that as folks move on – older folks retire or others shift to new roles – businesses simply aren't backfilling those managerial positions,' he says. The change is largely driven by cost pressures. 'We've seen the average labour cost increase nearly 20 per cent over the last couple of years,' Mr. Tremper says. 'Small businesses don't have a lot of leeway in their budgets, so they're thinking through how best to maximize the productivity of the folks they have on staff. Part of that has come down to reducing management layers.' But the consequences of a leaner org chart extend beyond budgets. What we lose when we flatten While some businesses may appreciate the savings and agility that come with fewer layers of hierarchy, Mr. Tremper cautions against seeing it as a purely positive shift. 'These middle managers are really important for organizations,' he says. 'You have strategic decisions and guidance coming from the highest level of management, but it's individual managers who are turning those directions into actionable steps.' In other words, fewer managers may mean faster decision-making in the short term, but also the risk of teams lacking mentorship, development and day-to-day leadership. 'Highly productive sectors tend to maintain more managers with smaller teams,' Mr. Tremper says. 'It suggests that first-line managers play a critical role in scaling their expertise, developing their teams and ultimately boosting productivity.' Even in lower-productivity industries, measured by total output per hour worked, Gusto found that businesses with a higher share of managers tend to outperform their peers. Managers are opting out, too Not only are businesses hiring fewer managers but existing ones are leaving. In late 2024, Gusto found that the quit rate among managers was about 10 per cent higher than it was in January 2022, when it was more of an employee-driven labour market. 'Quit rates are often viewed as a sign of labour market confidence,' says Mr. Tremper. 'If managers are leaving, it could mean they believe they can find more meaningful work elsewhere. They might be looking to lead teams at other companies or return to being high-performing individual contributors.' Some may even be taking the opportunity to pivot entirely. 'For folks who are maybe no longer managers, this could be a chance to ask: What path do I really want? Do I want to be an individual expert? Or maybe this is the time to start my own business or consulting practice.' Flattening with intention The Great Flattening may seem like a cost-saving trend but it comes with trade-offs. While it can boost short-term agility, businesses that cut too deeply may sacrifice long-term development and stability. Mr. Tremper says business leaders should think carefully about what they're giving up. 'When I think of the most effective managers I've had, they've cared deeply about my professional development. They created opportunities for me to grow beyond my current skill set,' he says. Small businesses especially, he adds, rely on strong teams and strong teams often rely on great managers. 11 per cent According to new data from book summary app company Headway, while many workers are enjoying a slow summer season, more than one in 10 say their workload has increased. Read more Experts say rebranding yourself is about more than a job title or what you wear. It's important to be authentic about how you're changing personally and professionally and share that story over time. On a more tactical level, you can also get new headshots, work with a coach and spend time connecting intentionally with your current network and new peers in your industry. Read more 'Being punctual is a form of non-verbal communication. By showing up on time, you're non-verbally telling that person you care enough about their time and the task at hand. It's a representation of your work ethic and competency,' says etiquette trainer Mariah Grumet Humbert. This article looks at how punctuality norms have evolved over time and how being chronically late can impact your personal brand at work and in life. Read more Robert Half research reveals that Gen Z and professionals in tech are the most likely to search for a new job in the next six months. For the first time since the staffing firm began tracking worker sentiment, the research shows better benefits and perks rank as the highest motivator for workers exploring new roles. Read more
